Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Nov;65(6):455–469. doi: 10.1016/j.curtheres.2005.01.002

An open-label comparison of the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) level in an Indian population with dyslipidemia

Kirandeep Kaur 1,*, Jaswant Rai 1, Geeta Sharma 1, Baljinder Singh Bal 1
PMCID: PMC3964561  PMID: 24672098

Abstract

Abstract

Background:

Patients with dyslipidemia often require the use of >1 lipid-altering agent to achieve the target levels recommended by the National Cholesterol Education Program Adult Treatment Panel III.

Objective:

The aim of this study was to compare the effects of simvastatin and niacin alone and combined on the lipid profile and lipoprotein (a) (Lp[a]) level in an Indian population with dyslipidemia.

Methods:

This 12-week, open-label, nonrandomized study was conducted at the Departments of Pharmacology and Medicine, Government Medical College, Amritsar (Punjab), India. Patients aged 30 to 70 years with dyslipidemia were eligible. Patients were assigned to 1 of 3 treatment groups. Group 1 received simvastatin 20 mg/d for 12 weeks. Group 2 received niacin at doses of 375 mg/d for 1 week, 500 mg/d for 1 week, and 500 mg BID for 10 weeks. Group 3 received simvastatin 10 mg/d plus niacin (375 mg for 1 week and 500 mg for 11 weeks). The lipid profile (low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], total cholesterol [TC], and triglycerides [TG]) and Lp(a) were measured before the start of therapy and at 6 and 12 weeks of treatment. Percentage changes from baseline were calculated. Adverse effects (AEs) were recorded at weeks 6 and 12 and through spontaneous reporting.

Results:

Ninety patients were enrolled (50 men, 40 women; 30 patients per treatment group). In group 1, the mean (SD) percentage decrease in LDL-C level at 12 weeks was 42.79% (16.29%) (P < 0.05), but no significant change was seen in group 2 or 3. The mean (SD) percentage increases in HDL-C level were 18.43% (13.28%) and 20.82% (17.57%) in groups 2 and 3, respectively (both, P < 0.05), but no significant change was seen in group 1. TC levels decreased by a mean (SD) of 32.97% (13.66%) in group 1 (P < 0.05), but no significant change was seen in group 2 or 3. TG and Lp(a) levels did not change significantly in any of the 3 treatment groups. Flushing, myalgia, and dyspepsia were the most common AEs in patients receiving niacin.

Conclusions:

In this study in Indian patients with dyslipidemia, simvastatin-niacin combination therapy was associated with greater changes in lipid profile compared with either agent used alone. Niacin was also associated with greater changes in Lp(a) levels. AEs were less prevalent with combination therapy than with niacin alone.

Key words: dyslipidemia, simvastatin, niacin, combination therapy

Full Text

The Full Text of this article is available as a PDF (548.0 KB).

References

  • 1.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
  • 2.Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill; Basel: 2001. pp. 971–1002. [Google Scholar]
  • 3.Knopp RH, Ginsberg J, Albers JJ. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism. 1985;34:642–650. doi: 10.1016/0026-0495(85)90092-7. [DOI] [PubMed] [Google Scholar]
  • 4.Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154:73–82. [PubMed] [Google Scholar]
  • 5.Martin-Jadraque R, Tato F, Mostazo JM. Effectiveness of low-dose crystalline nicotinic acid in men with low high-density lipoprotein cholesterol levels. Arch Intern Med. 1996;156:1081–1088. [PubMed] [Google Scholar]
  • 6.Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271–276. doi: 10.1111/j.1365-2796.1989.tb01393.x. [DOI] [PubMed] [Google Scholar]
  • 7.Enas EA, Yusuf S, Mehta JL. Prevalence of coronary artery disease in Asian Indians. Am J Cardiol. 1992;70:945–949. doi: 10.1016/0002-9149(92)90744-j. [DOI] [PubMed] [Google Scholar]
  • 8.Enas EA, Mehta JL. Malignant atherosclerosis in young Indians. Thought on pathogenesis. Prevention and treatment. Clin Cardiol. 1995;18:131–135. doi: 10.1002/clc.4960180305. [DOI] [PubMed] [Google Scholar]
  • 9.Sandholzer C, Halman DM, Sahe N. Effect of apolipoprotein (a) polymorphism on the lipoprotein (a) concentration in seven ethnic groups. Hum Genet. 1991;86:607–614. doi: 10.1007/BF00201550. [DOI] [PubMed] [Google Scholar]
  • 10.Allain CC, Poon LS, Chan CS. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;29:470–475. [PubMed] [Google Scholar]
  • 11.Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583–595. [PubMed] [Google Scholar]
  • 12.Bucolo G, David H. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem. 1973;19:476–482. [PubMed] [Google Scholar]
  • 13.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
  • 14.Metzmann E. Protein quantitation on both branches of the Heidelberger curve by monitoring the kinetic of immunoprecipitation. Behring Inst Mitt. 1985;78:167–175. [PubMed] [Google Scholar]
  • 15.Enas EA, Garg A, Davidson MA. Coronary heart disease and its risk factors in the first-generation immigrant Asian Indians to the United States of America. Indian Heart J. 1996;48:343–353. [PubMed] [Google Scholar]
  • 16.Jalowiec DA, Hill JA. Myocardial infarction in the young and in women. Cardiovasc Clin. 1989;20:197–206. [PubMed] [Google Scholar]
  • 17.Sharma SN, Kaul U, Sharma S. Coronary arteriographic profile in young and old Indian patients with ischaemic heart disease: A comparative study. Indian Heart J. 1990;42:365–369. [PubMed] [Google Scholar]
  • 18.Dave TH, Wasir HS, Prabhakaran D. Profile of coronary artery disease in Indian women: Correlation of clinical, non invasive and coronary angiographic findings. Indian Heart J. 1991;43:25–29. [PubMed] [Google Scholar]
  • 19.Negus BH, Willard JE, Glamann DB. Coronary anatomy and prognosis of young, asymptomatic survivors of myocardial infarction. Am J Med. 1994;96:354–358. doi: 10.1016/0002-9343(94)90066-3. [DOI] [PubMed] [Google Scholar]
  • 20.Enas EA, Yusuf S, Garg A. Lipoprotein (a) levels in Indian physicians. Comparison with black and white physicians in the U.S.A. Indian Heart J. 1994;46:185. (Suppl) [Google Scholar]
  • 21.Enas EA, Yusuf S. Third meeting of the International Working Group on Coronary Artery Disease in South Asians; 29 March 1998, Atlanta, USA; 1999. pp. 99–103. [PubMed] [Google Scholar]
  • 22.Low PS, Heng CK, Saha N, Tay JS. Racial variation of cord plasma lipoprotein(a) levels in relation to coronary risk level: A study in three ethnic groups in Singapore. Pediatr Res. 1996;40:718–722. doi: 10.1203/00006450-199611000-00011. [DOI] [PubMed] [Google Scholar]
  • 23.Gopinath N, Chadha SL, Sehgal A. What is ‘desirable’ lipid profile. Indian Heart J. 1994;46:325–327. [PubMed] [Google Scholar]
  • 24.Guyton JR, Blazing MA, Hagar J. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177–1184. doi: 10.1001/archinte.160.8.1177. [DOI] [PubMed] [Google Scholar]
  • 25.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. [PubMed] [Google Scholar]
  • 26.Sweany AE, Shapiro DR, Tate AC, for the NIDDM Study Group Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus. Clin Ther. 1995;17:186–203. doi: 10.1016/0149-2918(95)80018-2. [DOI] [PubMed] [Google Scholar]
  • 27.Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol. 1998;81:66B–69B. doi: 10.1016/s0002-9149(98)00041-1. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES